FATE THERAPEUTICS INC (FATE)

Every figure this model derived for FATE, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 3,714,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 153,770,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 157,953,000 AssetsCurrent 2026-06-30
current liabilities 32,592,000 LiabilitiesCurrent 2026-06-30
equity 153,438,000 StockholdersEquity 2026-06-30
ocf -101,910,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 6,491,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 17,836,000 AllocatedShareBasedCompensationExpense 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up FATE on one particular measure came for.

RatioValue
cash operating margin-1598.61
current ratio4.85
current ratio reported4.85
deferred revenue growth0.0
dilution pct4.49
fcf margin-1627.24
operating margin-2058.08
revenue growth-23.36
revenue growth per share-26.66
rule of 40-2081.45
sbc pct revenue274.78

What to be careful about

What this model itself distrusts about FATE's figures. Written by the derivation as it ran, not added afterwards.